Hydroxychloroquine pleiotropic benefits: is there any evidence beyond rheumatological diseases?

Anil Pareek; Siddharth Nikam

doi:10.18203/2320-6012.ijrms20242642

Authors

Anil Pareek Medical Affairs and Clinical Research, Ipca laboratories Limited, Kandivali Industrial Estate, Mumbai, Maharashtra, India https://orcid.org/0000-0002-5048-1629
Siddharth Nikam Medical Affairs and Clinical Research, Ipca laboratories Limited, Kandivali Industrial Estate, Mumbai, Maharashtra, India https://orcid.org/0009-0003-5857-4226

DOI:

https://doi.org/10.18203/2320-6012.ijrms20242642

Keywords:

Hydroxychloroquine, Rheumatoid arthritis, Systemic lupus erythematosus, Type 2 diabetes

Abstract

Once used as an antimalarial medication, hydroxychloroquine (HCQ) is now widely used to treat a variety of rheumatic diseases, including rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). HCQ has shown benefits in rheumatic diseases because of its anti-inflammatory and immunomodulatory properties. HCQ has demonstrated cardioprotective effects in rheumatic disorders, including SLE and RA. Recently, the role of inflammatory mediators has drawn a lot of attention in the pathophysiology of prediabetes, type 2 diabetes (T2D), diabetic complications and atherosclerotic cardiovascular diseases (ASCVD). In a prospective observational study of RA patients, taking HCQ for longer than four years, the incidence of diabetes has been found to be substantially decreased. In a mechanistic human pharmacodynamic study of T2D patients, HCQ showed improvements in insulin resistance and beta-cell function. These outcomes are associated with reductions in inflammatory markers such as interleukin 6 (IL6) and high-sensitivity C-reactive protein (hs-CRP). With its anti-hyperglycemic potential, anti-inflammatory, and pleiotropic effects (lipid-lowering, antiplatelet, antithrombotic) HCQ stands out as a therapeutic option that is affordable for patients with uncontrolled T2D who are at risk for complications. The pleiotropic benefits of HCQ extend beyond rheumatic diseases with potential in prediabetes, T2D and ASCVD.

Metrics

Metrics Loading ...

References

Nirk El, Reggiori F, Mauthe M. Hydroxychloroquine In Rheumatic Autoimmune Disorders And Beyond. Embo Mol Med. 2020;12(8):e12476.

Chen Ch, Chen Ha, Liao Ht, Chen Ch. Hydroxychloroquine Exposure Reduces The Risk Of Cardiovasular Disease Events In Patients With Hypertension Or Diabetes Mellitus. Clin Exp Rheumatol. 2023;24.

Liu D. Pms16 Effects Of Hydroxychloroquine On Thrombosis Factors And Inflammatory Cytokines In Patients With Elderly Rheumatoid Arthritis. Value in Health. 2019;22(3):S696.

Yang J, Yang X, Yang J, Li M. Hydroxychloroquine Inhibits The Differentiation Of Th17 Cells In Systemic Lupus Erythematosus. J Rheumatol. 2018;45(6):818-26.

Sattar N. Type 2 diabetes as an inflammatory disorder. Br J Diabetes Vasc Dis. 2003;3:36-41.

Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001;286:327-34.

Barzilay JI, Abraham L, Heckbert SR, Cushman M, Kuller LH, Resnick HE, et al. The relation of markers of inflammation to the development of glucose disorders in the elderly: the Cardiovascular Health Study. Diabetes. 2001;50:2384-9.

Festa A, D'Agostino R Jr, Tracy RP, Haffner SM. The Insulin Resistance Atherosclerosis Study. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes. 2002;51:1131-7.

Lindsay RS, Funahashi T, Hanson RL, Matsuzawa Y, Tanaka S, Tataranni PA, et al. Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet. 2002;360:57-8.

Wasko MC, Hubert HB, Lingala VB, Elliott JR, Luggen ME, Fries JF, et al. Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis. JAMA. 2007;298(2):187-93.

Ozen G, Pedro S, Holmqvist ME, Avery M, Wolfe F, Michaud K. Risk of diabetes mellitus associated with disease-modifying antirheumatic drugs and statins in rheumatoid arthritis. Ann Rheum Dis. 2017;76(5):848-54.

Sheikhbahaie F, Amini M, Gharipour M, Aminoroaya A, Taheri N. The effect of hydroxychloroquine on glucose control and insulin resistance in the prediabetes condition. Adv Biomed Res. 2016;5:145.

Penn SK, Kao AH, Schott LL, Elliott JR, Toledo FG, Kuller L, et al. Hydroxychloroquine and glycemia in women with rheumatoid arthritis and systemic lupus erythematosus. J Rheumatol. 2010;37(6):1136-42.

Mercer E, Rekedal L, Garg R, Lu B, Massarotti EM, Solomon DH. Hydroxychloroquine improves insulin sensitivity in obese non-diabetic individuals. Arthritis Res Ther. 2012;14(3):R135.

Wasko MC, McClure CK, Kelsey SF, Huber K, Orchard T, Toledo FG. Antidiabetogenic effects of hydroxychloroquine on insulin sensitivity and beta cell function: a randomised trial. Diabetologia. 2015;58(10):2336-43.

Toledo FGS, Miller RG, Helbling NL, Zhang Y, DeLany JP. The effects of hydroxychloroquine on insulin sensitivity, insulin clearance and inflammation in insulin-resistant adults: A randomized trial. Diabetes Obes Metab. 2021;23(6):1252-61.

Abdel-Hamid AA, El-Firgany Ael-D. Hydroxychloroquine hindering of diabetic isletopathy carries its signature on the inflammatory cytokines. J Mol Histol. 2016;47(2):183-93.

Quatraro A, Consoli G, Magno M, Caretta F, Nardozza A, Ceriello A, et al. Hydroxychloroquine in decompensated, treatment-refractory noninsulin-dependent diabetes mellitus. A new job for an old drug? Ann Intern Med. 1990;112(9):678-81.

Gerstein HC, Thorpe KE, Taylor DW, Haynes RB. The effectiveness of hydroxychloroquine in patients with type 2 diabetes mellitus who are refractory to sulfonylureas--a randomized trial. Diabetes Res Clin Pract. 2002;55(3):209-19.

Hsia SH, Duran P, Lee ML, Davidson MB. Randomized controlled trial comparing hydroxychloroquine with pioglitazone as third-line agents in type 2 diabetic patients failing metformin plus a sulfonylurea: A pilot study. J Diabetes. 2020;12(1):91-4.

Pareek A, Chandurkar N, Thomas N, Viswanathan V, Deshpande A, Gupta OP, et al. Efficacy and safety of hydroxychloroquine in the treatment of type 2 diabetes mellitus: a double blind, randomized comparison with pioglitazone. Curr Med Res Opin. 2014;30(7):1257-66.

Pareek A, Chandurkar N, Mehta R, Naidu K. Evaluation of safety and efficacy of hydroxychloroquine sulfate as an adjunct to diet and exercise to improve glycemic control in type 2 diabetes patients uncontrolled on sulfonylureas + metformin combination. World J Pharm Res. 2023;12(18):590-610.

Baidya A, Chakravarti HN, Saraogi RK, Gupta A, Ahmed R, et al. Efficacy of Maximum and Optimum Doses of Hydroxychloroquine Added to Patients With Poorly Controlled Type 2 Diabetes on Stable Insulin Therapy along with Glimepiride And Metformin: Association of High-Sensitive C-Reactive Protein (Hs-CRP) and Glycosylated Haemoglobin (Hba1c). Endocrinol Metab Syndr. 2018;7:283.

Baidya A, Pattanaik SR, Shankar A, Ahmed R, Dora N, Behera S. Efficacy and Safety of Hydroxychloroquine as an Add-On Therapy in Indian Patients with Type 2 Diabetes Mellitus Inadequately Controlled With Two Oral Drug Combination and Basal Insulin: A 72 Week Observational Trial. Int J Res Rev. 2019;6(11):218-24.

Rajput R, Upadhyay P, Rajput S, Saini S, Kharab S. Effect of hydroxychloroquine on beta cell function, insulin resistance, and inflammatory markers in type 2 diabetes patients uncontrolled on glimepiride and metformin therapy. Int J Diabetes Dev Ctries. 2023;4:1-6.

Chakravarti HN, Nag A. Efficacy and safety of hydroxychloroquine as add-on therapy in uncontrolled type 2 diabetes patients who were using two oral antidiabetic drugs. J Endocrinol Invest. 2021;44(3):481-92.

Rajput R, Saini S, Rajput S, Upadhyay P. Effect of Hydroxychloroquine on Glycemic Variability in Type 2 Diabetes Patients Uncontrolled on Glimepiride and Metformin Therapy. Indian J Endocrinol Metab. 2022;26(6):537-42.

Kerr G, Aujero M, Richards J, Sayles H, Davis L, Cannon G, et al. Associations of hydroxychloroquine use with lipid profiles in rheumatoid arthritis: pharmacologic implications. Arthritis Care Res (Hoboken). 2014;66(11):1619-26.

Petri M. Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis. Lupus. 1996;5(1):S16-22.

Pareek A, Chandurkar N, Thulaseedharan NK, Legha R, Agarwal M, Mathur SL, et al. Efficacy and safety of fixed dose combination of atorvastatin and hydroxychloroquine: a randomized, double-blind comparison with atorvastatin alone among Indian patients with dyslipidemia. Curr Med Res Opin. 2015;31(11):2105-17.

Singh UP, Baidya A, Singla M, Jain S, Kumar S, Sarogi RK, et al. Efficacy and safety of substituting teneligliptin with hydroxychloroquine in inadequately controlled type II diabetes subjects with combination therapy of teneligliptin, metformin, and glimepiride with or without another antidiabetic therapy: the TENE-HYQ SHIFT study. Clin Diabetol. 2018;7(5):209-14.

Achuthan S, Ahluwalia J, Shafiq N, Bhalla A, Pareek A, Chandurkar N, et al. Hydroxychloroquine's Efficacy as an Antiplatelet Agent Study in Healthy Volunteers: A Proof of Concept Study. J Cardiovasc Pharmacol Ther. 2015;20(2):174-80.

Nuri E, Taraborelli M, Andreoli L, Tonello M, Gerosa M, Calligaro A, et al. Long-term use of hydroxychloroquine reduces antiphospholipid antibodies levels in patients with primary antiphospholipid syndrome. Immunol Res. 2017;65(1):17-24.

Hansen EH, Jessing P, Lindewald H, Ostergaard P, Olesen T, Malver EI. Hydroxychloroquine sulphate in prevention of deep venous thrombosis following fracture of the hip, pelvis, or thoracolumbar spine. J Bone Joint Surg Am. 1976;58(8):1089-93.

Carter AE, Eban R. Prevention of postoperative deep venous thrombosis in legs by orally administered hydroxychloroquine sulphate. Br Med J. 1974;3(5923):94-5.

Wu CL, Chang CC, Kor CT, Yang TH, Chiu PF, Tarng DC, et al. Hydroxychloroquine Use and Risk of CKD in Patients with Rheumatoid Arthritis. Clin J Am Soc Nephrol. 2018;13(5):702-9.

Pons-Estel GJ, Alarcón GS, McGwin G Jr, Danila MI, Zhang J, Bastian HM, et al; Lumina Study Group. Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort. Arthritis Rheum. 2009;61(6):830-9.

Pareek A. Treatment and prophylaxis of kidney diseases. Us 2016/00304.15 a1. 2016.

Baidya A, Guha S, Kumar S, Shankar A. Effect of hydroxychloroquine on hba1c and lipid parameters in t2dm subjects with diabetic neuropathy who are on statins. Diabetes. 2020;69(1):585.

Sharma TS, Wasko MC, Tang X, Vedamurthy D, Yan X, Cote J, et al. Hydroxychloroquine Use Is Associated With Decreased Incident Cardiovascular Events in Rheumatoid Arthritis Patients. J Am Heart Assoc. 2016;5(1):e002867.

Shapiro M, Levy Y. The association between hydroxychloroquine treatment and cardiovascular morbidity among rheumatoid arthritis patients. Oncotarget. 2017;9(5):6615-22.

Haugaard JH, Dreyer L, Ottosen MB, Gislason G, Kofoed K, Egeberg A. Use of hydroxychloroquine and risk of major adverse cardiovascular events in patients with lupus erythematosus: A Danish nationwide cohort study. J Am Acad Dermatol. 2021;84(4):930-7.

Ulander L, Tolppanen H, Hartman O, Rissanen TT, Paakkanen R, Kuusisto J, et al. Hydroxychloroquine reduces interleukin-6 levels after myocardial infarction: The randomized, double-blind, placebo-controlled OXI pilot trial. Int J Cardiol. 2021;337:21-7.

Pareek A. Hydroxychloroquine: The First Anti-inflammatory Drug Approved in Type 2 Diabetes. A textbook of Inflammation as a therapeutic target in T2D. IJCP. 2019;94-101.